All In Biotech

Drug Trial Radar · NCT04714294

Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers

To Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers: a Randomized, Double-blind, Placebo-controlled, Dose Escalation Phase I Clinical Study

Last checked: Nov 19, 2026Latest source record: Jan 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

84

Planned (sponsor's estimate)

Start

Sep 8, 2020

Primary completion

May 31, 2021

Study completion May 31, 2021

Sponsor

Lead sponsor
Newsoara Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Jan 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Chronic obstructive pulmonary disease (COPD) is a common, preventable and treatable disease characterized by persistent respiratory symptoms and incompletely reversible airflow limitation. It is usually caused by airway and / or alveolar abnormalities caused by obvious exposure to toxic particles or gases.COPD is currently the fourth leading cause of death in the world, and is expected to be the third leading cause of death by 2020.HPP737 as an oral PDE4 inhibitor for the treatment of COPD.Preclinical data showed that the activity of HPP737 was similar to that of rofloxacin, but HPP737 significantly reduced the permeability to CNS and may have better tolerance. HPP737 will be used to develop indications for chronic obstructive pulmonary disease, and PK study in Chinese people is going to to evaluate the safety and tolerability of HPP737 in healthy volunteers.

Conditions

  • Healthy

Interventions

  • HPP737 or placeboDrug

    HPP737 or placebo will be randomized to assign to subjects

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate changes of Safety and tolerability from day 1 to day 7 (SAD) or day 14(MAD)Time frame: SAD: from the screening period to the 7th day; MAD: from the screening period to the 14th day;

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Affiliated Hangzhou First People's Hospital.Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.